News

Can-Fite BioPharma Secures $175 Million for Cancer Drug Trials

Can-Fite BioPharma Secures $175 Million for Cancer Drug Trials

Can-Fite BioPharma Raises Significant Funding for Clinical Trials

Can-Fite BioPharma Ltd., a prominent biopharmaceutical company, has made headlines by securing a total of $175 million in funding. This financial boost is fundamental as it enables the company to propel its innovative drug candidates, Namodenoson and Piclidenoson, into crucial Phase III clinical trials. These trials are focused on complex conditions such as liver cancer and psoriasis, which often have high unmet medical needs.

The Importance of Namodenoson and Piclidenoson in Cancer Treatment

Can-Fite is recognized for its pioneering work in developing small-molecule therapeutics that specifically target the A3 adenosine receptor (A3AR). This receptor is highly expressed in many types of inflammatory and cancerous cells, making it a strategic target for treatment. Namodenoson, designed for oral use, is currently undergoing Phase III trials for advanced liver cancer, showcasing its ability to selectively attack tumor cells while conserving surrounding healthy tissues.

In parallel, Piclidenoson, which also boasts an oral administration option, is advancing through a pivotal trial aimed at treating moderate-to-severe psoriasis. Both drug candidates not only exhibit favorable safety records but also have demonstrated strong anti-cancer and anti-inflammatory properties in previous trials.

Funding Impact on Drug Development and Manufacturing

This substantial funding also aids in drug manufacturing, regulatory activities with key health authorities such as the FDA and EMA, and the formulation of an extensive intellectual property portfolio that protects Can-Fite’s innovations. With a commitment to comprehensive development, Can-Fite aims to ensure that their drug candidates can reach the market effectively once they receive regulatory approval.

The company's ambitious goals don’t stop at liver cancer and psoriasis. Can-Fite is also investigating the application of Namodenoson in different types of cancers, such as pancreatic cancer. Ongoing studies, including a Phase IIa trial, aim to explore the potential of this compound in halting tumor growth through modulation of critical signaling pathways.

Commercial Partnerships and Future Prospects

In its strategic growth plan, Can-Fite has established seven commercialization agreements with various strategic partners, setting the stage for the future marketing of its drugs post-regulatory approval. The leadership, including CEO Motti Farbstein, emphasizes the significance of these partnerships as indicators of trust and confidence from investors and collaborators in Can-Fite’s clinical initiatives.

“This funding milestone reflects the strong confidence our investors and partners have in Can-Fite’s scientific platform and clinical strategy,” said Farbstein. He further noted that moving into crucial Phase III clinical trials represents significant progress toward delivering innovative oral therapies to patients battling serious conditions.

Can-Fite's Vision and Drug Pipeline

Can-Fite BioPharma operates within a multi-billion dollar market focused on cancers and inflammatory diseases, driven by cutting-edge research and development. Their drug candidates, particularly Namodenoson and Piclidenoson, are part of a larger vision to address unmet medical needs not just within oncology, but also in conditions like metabolic dysfunction-associated steatohepatitis (MASH).

Namodenoson has already achieved Orphan Drug Designation in both the U.S. and Europe, along with Fast Track Designation for the second-line treatment of liver cancer in the U.S. This designation provides a pathway for expedited development and review of potentially significant therapies. Additionally, Can-Fite is actively pursuing the efficacy of other drug candidates like CF602 for erectile dysfunction, highlighting its diversified approach to drug development.

Conclusion

As Can-Fite BioPharma progresses through its clinical and strategic pathways, it remains dedicated to transforming the treatment landscape through innovative therapies. The recent funding and ongoing trials reflect a strong commitment to advancing drug development aimed at improving patient outcomes in liver cancer, psoriasis, and beyond.

Frequently Asked Questions

What is the significance of the $175 million funding for Can-Fite?

This funding is crucial for advancing Can-Fite's key drug candidates through pivotal Phase III clinical trials, enhancing its growth and development capabilities.

What conditions are Namodenoson and Piclidenoson targeting?

Namodenoson is primarily targeted at advanced liver cancer, while Piclidenoson focuses on treating moderate-to-severe psoriasis.

What role does the A3 adenosine receptor play in Can-Fite's drugs?

The A3 adenosine receptor (A3AR) is a target for Can-Fite's drugs, which have been designed to selectively act on cancerous and inflammatory cells.

How is Can-Fite's intellectual property portfolio structured?

Can-Fite's intellectual property portfolio is extensive, providing robust protection for its drug innovations and supporting its strategic development efforts.

What future studies is Can-Fite planning beyond liver cancer and psoriasis?

Can-Fite is continuing to explore the use of Namodenoson in various cancers, including pancreatic cancer, showcasing its dedication to expanding its research frontiers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 56

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 63

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 234

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 11

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 53

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading

Top 5 Most Recently Viewed Articles

FlexShopper Partners with PayPossible to Enhance Payment Solutions

Updated Category News Views 152

FlexShopper Enhances Consumer Payment Solutions FlexShopper Inc., a leading name in lease-to-own (LTO) retail and payment solutions, is thrilled to share the news of its strategic partnership with PayPossible. This collaboration focuses on expanding flexible financing options for consumers through the integration of FlexShopper’s services into PayPossible’s renowned...

Continue Reading
SanDisk Set to Thrive Amid Rising AI Demand and Supply Gaps

Updated Category News Views 356

SanDisk Corporation and the Promise of AI Demand SanDisk Corporation (NASDAQ: SNDK) is experiencing a wave of investor optimism as shares surged recently. This positive sentiment primarily stems from the anticipated growth in the NAND flash memory market, driven by increasing demand from AI data centers and limited supply conditions. Market Dynamics and Future Performance...

Continue Reading
Exciting Preparations for FIFA World Cup 26 in Miami

Updated Category News Views 437

Countdown to FIFA World Cup 26 in Miami Greater Miami and Miami Beach: A Hub for Global Sports As we approach a thrilling year leading up to the FIFA World Cup 26™, anticipation builds across Greater Miami. Miami is set to solidify its status as a global sports capital, ready to host seven electrifying matches at the Hard Rock Stadium. The preparations are underway for...

Continue Reading
JKB and IFC's Bold Green Bond Move Spurs Finance

Updated Category News Views 22

Amman Sets the Stage for Green Finance Watch out, folks! Jordan Kuwait Bank (JKB), teaming up with the International Finance Corporation (IFC), is stirring the pot in Amman with its second Green Bond. This is no small fry—it’s a big-time financial ballet with a USD 100 million investment aimed squarely at reshaping the landscape of sustainable finance in Jordan....

Continue Reading
Discover Modern Living at Modera St. Paul in Dallas

Updated Category News Views 194

Modera St. Paul Opens Doors to New Residents Mill Creek Residential has recently welcomed its first residents to Modera St. Paul, a striking mixed-use community positioned in the heart of Dallas. This development adds a total of 333 homes alongside street-level retail space, creating a vibrant urban living experience. A Prime Location for Modern Living Situated at a key...

Continue Reading